Navigation Links
Salix Pharmaceuticals Commits $1.125M to AGA Research Foundation
Date:3/13/2013

BETHESDA, Md., March 13, 2013 /PRNewswire-USNewswire/ -- The American Gastroenterological Association (AGA) Research Foundation is pleased to welcome Salix Pharmaceuticals as a supporter of the foundation's endowment.

The AGA Research Foundation provides research funding grants to young investigators in gastroenterology and hepatology.  The foundation's grants transform young researchers' lives by encouraging them to embark on and continue careers in research. Many ultimately make discoveries that improve patient care.

Salix Pharmaceuticals is a specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal (GI) disorders. 

"AGA is committed to helping young scientists investigate the GI and liver diseases that plague millions of people. AGA-funded researchers hold the keys to the patient care advances of tomorrow. AGA is thrilled that Salix recognizes the importance of supporting discovery and has made a significant commitment to the AGA Research Foundation for years to come," said Nicholas F. LaRusso , MD, AGAF, chair of the AGA Research Foundation.

Salix Pharmaceuticals' $1.125 million, five-year commitment to the AGA Research Foundation endowment will help ensure that researchers have the tools they need to discover ways to better diagnose, treat and cure digestive diseases.

"Salix is passionate about providing solutions to address unmet treatment needs for people with GI disorders," said Carolyn Logan , president and chief executive officer, Salix Pharmaceuticals.  "We are pleased to support the AGA Research Foundation in its mission of the advancement of gastroenterological and hepatological research."

Many breakthroughs have been achieved through gastroenterological and hepatological research over the past century, forming the basis of the modern medical practice. The AGA Research Foundation is working to continue this tradition of discovery and ultimately improve the lives of patients with digestive diseases through the researchers it funds. Salix's support of the AGA Research Foundation's mission is a critical investment in the future of the field of gastroenterology.

About the AGA Research Foundation
The AGA Research Foundation is the foundation of the American Gastroenterological Association (AGA), the leading professional society representing gastroenterologists and hepatologists worldwide. The mission of the foundation is to raise funds to support young researchers in gastroenterology and hepatology. The AGA Research Foundation awards nearly $1.2 million in research grants annually. www.gastro.org/foundation

About Salix Pharmaceuticals
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.

Salix markets XIFAXAN® (rifaximin) tablets 200 mg and 550 mg, MOVIPREP® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP®  (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO® (mesalamine) extended-release capsules 0.375 g, GIAZO™ (balsalazide disodium) tablets, COLAZAL® (balsalazide disodium) Capsule, METOZOLV® ODT (metoclopramide HCl), RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection, FULYZAQ™ (crofelemer) delayed-release tablets, SOLESTA®, DEFLUX®, PEPCID® (famotidine) for Oral Suspension, DIURIL® (Chlorothiazide) Oral Suspension, AZASAN® (Azathioprine) Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, RELISTOR® , LUMACAN™ and rifaximin for additional indications are under development.

For full prescribing information and important safety information on Salix products, including BOXED WARNINGS for OSMOPREP, AZASAN and METOZOLV, please visit www.salix.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP".

For more information, please visit our Website at www.salix.com or contact the Company at 919-862-1000. Follow us on Twitter (@SalixPharma) and Facebook (www.facebook.com/SalixPharma). Information on our Twitter feed, Facebook page and web site is not incorporated in our SEC filings.

Many breakthroughs have been achieved through gastroenterological and hepatological research over the past century, forming the basis of the modern medical practice. The AGA Research Foundation is working to continue this tradition of discovery and ultimately improve the lives of patients with digestive diseases through the researchers it funds. Salix's support of the AGA Research Foundation's mission is a critical investment in the future of the field of gastroenterology.


'/>"/>
SOURCE American Gastroenterological Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
2. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
3. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
4. Imprimis Pharmaceuticals Announces Underwriter Exercise of Over-Allotment Option
5. Isis Pharmaceuticals Reports Clinical Data Showing Blunting of Severe Increases in CRP Following Endotoxin Challenge With ISIS-CRP Rx
6. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
7. N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
8. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
9. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology:
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the placement ... Vice President of North American Capital Sales at HTG Molecular . ... in the commercialization of the HTG EdgeSeq system and associated reagents in North America. ...
Breaking Medicine News(10 mins):